Neurogene Inc. 8-K

What Happened

• Neurogene Inc. filed a Form 8-K on April 20, 2026, reporting that its Board expanded to seven directors and appointed Christine Mikail (the Company’s President and Chief Financial Officer) as a Class II director. Her term as director will expire at the 2028 annual meeting of stockholders.
• The company also issued a press release the same day announcing the appointment of Christina Shafer as Chief Commercial Officer.

Key Details

• Effective date: April 20, 2026.
• Board size: expanded to seven directors; Ms. Mikail fills the newly created vacancy.
• Director term: Ms. Mikail is a Class II director with a term through the 2028 annual meeting.
• Executive roles and compensation: Ms. Mikail has served as Neurogene’s President & CFO since December 2023 (and at Neurogene OpCo since September 2019); she will not receive additional compensation for serving as a director. The filing states no related-party arrangement prompted her appointment.

Why It Matters

• This is a governance and leadership update: the company’s President & CFO now also serves on the public company Board, which centralizes executive and board responsibilities for an internal executive.
• Investors should note the board expansion and that the company publicly announced a new Chief Commercial Officer (Christina Shafer), both of which could affect corporate strategy and oversight going forward. The filing conveys these changes are internal appointments and that no extra director pay was granted.